U.S. Markets open in 4 hrs 44 mins

Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down as much as 20%, there are deals all over the place in the biotechnology sector. You should take advantage of them.

One of our favorite oversold opportunities in the biotech market right now is BioRestorative Therapies, Inc. (BRTX) a life sciences company focused on stem cell-based therapies. BRTX has been receiving positive findings on their lead cell therapy candidate BRTX-100. Now is a great time to start your research on BRTX.

Companies to put on your radar include: BioRestorative Therapies, Inc. (BRTX), EyeGate Pharmaceuticals, Inc. (EYEG), OrganiGram Holdings, Inc. (OGRMF), AVEO Pharmaceuticals, Inc. (AVEO) and Exelixis, Inc. (EXEL).

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $8.99M Share Price: $1.00

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, announced the appointment of Lance Alstodt as Executive Vice President and Chief Strategy Officer. In this capacity, Mr. Alstodt will be responsible for developing and refining the Company's overall strategy and implementing investment decisions. Mr. Alstodt brings over 25 years of experience in operations, strategy and mergers & acquisitions.

EyeGate Pharmaceuticals, Inc. (EYEG)

Market Cap: $18.24M Share Price: $0.42

EyeGate Pharmaceuticals, Inc. (EYEG) announced financial results for the three-month period ended September 30, 2018 and provided an update on recent corporate and operational activities.

Stephen From, EyeGate's Chief Executive Officer, said, "The third quarter of 2018 was a transformative quarter for EyeGate, with the Company receiving FDA approval for two IDE submissions for our Ocular Bandage Gel ('OBG') product, as well as focusing our efforts toward the key clinical trials that support this innovative product." Mr. From continued, "We are extremely pleased to have announced positive top-line data in each of our OBG studies for photorefractive keratectomy ('PRK') surgery and punctate epitheliopathies ('PE'). We are very happy with the data and believe that all of our data is sufficient and robust enough to create a path toward regulatory filings for approval and commercialization."

OrganiGram Holdings, Inc. (OGRMF)

Market Cap: $545.05M Share Price: $4.08

Organigram Holdings Inc., a leading licensed producer of medical marijuana, recently announced its medicinal cannabis plants and growing process has been certified organic with Ecocert Canada.

AVEO Pharmaceuticals, Inc. (AVEO)

Market Cap: $298.77M Share Price: $1.86

AVEO Pharmaceuticals (AVEO) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this cancer drug company would post a loss of $0.06 per share when it actually produced a loss of $0.15, delivering a surprise of -150%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Exelixis, Inc. (EXEL)

Market Cap: $4.97B Share Price: $16.65

Exelixis, Inc. (EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new medicines for difficult-to-treat cancers.

The company discovered its three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib) and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to received a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.


Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications, LLC